Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
Sign Up to like & getrecommendations! Published in 2018 at "Translational Oncology"
DOI: 10.1016/j.tranon.2018.01.002
Abstract: OBJECTIVE: A previous phase-2 trial to assess the addition of Endostar to gemcitabine and cisplatin (GC) chemotherapy showed that it improves prognosis in metastatic nasopharyngeal carcinoma (M-NPC) but the study cohort was small. We wished… read more here.
Keywords: chemotherapy; cisplatin chemotherapy; gemcitabine cisplatin; day ... See more keywords
A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Clinical Practice"
DOI: 10.1155/2022/5954379
Abstract: Objective The significance of this article is to talk about aprepitant and olanzapine 5 mg, compare them, and deeply explore the safety or effectiveness during the whole process of multiple-day cisplatin chemotherapy-induced vomiting and nausea. Methods… read more here.
Keywords: olanzapine aprepitant; day cisplatin; cisplatin chemotherapy; chemotherapy ... See more keywords
Recent advances in the contribution of circRNAs to cisplatin chemotherapy resistance in cancers.
Sign Up to like & getrecommendations! Published in 2021 at "Neoplasma"
DOI: 10.4149/neo_2021_210624n846
Abstract: Worldwide, cancer is a serious threat to the health of citizens of every country, with the incidence and mortality increasing year by year. Cisplatin is the first-line anticancer drug commonly used in clinics and is… read more here.
Keywords: resistance; recent advances; cisplatin chemotherapy; resistance cancers ... See more keywords